Background: Whether rosiglitazone use in patients with type 2 diabetes may affect thyroid cancer risk has not been investigated.
Methods: The reimbursement databases of all diabetic patients under oral anti-diabetic agents or insulin from 1996 to 2009 were retrieved from the National Health Insurance of Taiwan. An entry date was set at 1 January 2006, and 887,665 patients with type 2 diabetes were followed for thyroid cancer incidence until the end of 2009 for ever-users, never-users, and subgroups of rosiglitazone exposure using tertile cut-offs for time since starting rosiglitazone, duration of therapy, and cumulative dose. Hazard ratios were estimated by Cox regression.
Results: There were 103,224 ever-users and 784,441 never-users, with respective numbers of incident thyroid cancer of 84 (0.08%) and 764 (0.10%), and respective incidence of 23.12 and 28.09 per 100,000 person-years. The overall multivariable-adjusted hazard ratio was not significant. However, in dose-response analyses, the adjusted hazard ratios (95% confidence intervals) were significant for the third tertile of duration of therapy (≥ 14 months) and cumulative dose (≥ 1,800 mg) for age ≥ 50 years: 0.53 (0.31-0.89) and 0.50 (0.29-0.87), respectively.
Conclusions: This study suggests that rosiglitazone use in patients with type 2 diabetes may reduce the risk of thyroid cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/07853890.2013.851865 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Thyroid cancer.
Med Clin (Barc)
January 2025
Servicio de Endocrinología y Nutrición, Hospital i Institut de Recerca Germans Trias i Pujol, Universitat Autònoma de Barcelona, España. Electronic address:
In recent decades, the diagnosis of thyroid cancer, especially the papillary type, has increased significantly due to the use of imaging techniques such as ultrasound. For this reason, it is essential to rationalize diagnosis and treatment, since the behavior of thyroid cancer varies from slow-progressing tumors to highly aggressive ones. The application of risk assessment systems for ultrasound images and the optimization of cytology incorporating molecular studies allows cases to be stratified in order to select therapy on an individual basis.
View Article and Find Full Text PDFAptamer-Antibody Birecognized Sandwich SERRS Biosensor in Accurate and Rapid Identification of Intraoperative Parathyroid Hormone.
Anal Chem
January 2025
State Key Laboratory of Physical Chemistry of Solid Surfaces, College of Chemistry and Chemical Engineering, College of Energy, Discipline of Intelligent Instrument and Equipment, Cancer Center and Department of Breast and Thyroid Surgery, Department of Ultrasound, Xiang'an Hospital of Xiamen University, School of Medicine, Laboratory Animal Center Xiamen University, Xiamen University, Xiamen 361005, China.
With the increasing incidence of thyroid cancer worldwide and the increasing demand for surgery, the risk of parathyroid injury is also increasing, which will lead to postoperative hypoparathyroidism (HP) and hypocalcemia. In order to improve the quality of life of patients after surgery, there is an urgent need to develop a novel platform that can identify the parathyroid gland immediately during surgery. The parathyroid gland promotes the increase of blood calcium concentration by secreting parathyroid hormone (PTH).
View Article and Find Full Text PDFThyroxine alleviates interstitial lung disease induced by combined radiotherapy and immunotherapy.
Cancer Lett
January 2025
Laboratory of Molecular Cardiology, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. Electronic address:
Immune checkpoint blockade (ICB) combined with radiotherapy (RT) has improved patients survival, but also increased the risk of pulmonary adverse effects (AEs). Therefore, to explore potential drug targets for interstitial lung disease (ILD), we investigated the interaction of ICB and RT in pulmonary AEs using the disproportionality analysis and COX regression. Genome-wide association studies, transcriptome analysis, and vivo models highlighted the role of programmed death-ligand-1 (PD-L1) in ILD.
View Article and Find Full Text PDFMolecular mechanism of long chain non coding RNA LINC00511 influencing breast cancer stem cells: Mechanism of VEGFR1 protein.
Int J Biol Macromol
January 2025
Department of Hepatobiliary Surgery, The First Affiliated Hospital, Jinan University, Guangzhou 510630, Guangdong, PR China; Department of Breast and Thyroid Surgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, PR China; Key Laloratory of Molecular Pathology in Tumors of Guangxi, Baise 533000, Guangxi, PR China; Department of Oncology-Pathology, Karolinska Institutet, Stockholm SE-17176, Sweden. Electronic address:
A comprehensive investigation into the mechanism of VEGFR1 protein in this process was undertaken. Lentivirus-mediated RNA interference was employed to inhibit the expression of LINC00511 in breast cancer cell lines, and changes in breast cancer stem cell markers, including CD44+/CD24-, were monitored using flow cytometry. Additionally, the interaction between VEGFR1 protein and LINC00511 and the activation of its downstream signaling pathway were investigated through co-immunoprecipitation (Co-IP) and Western blot techniques.
View Article and Find Full Text PDFSLC26A9 promotes the initiation and progression of breast cancer by activating the PI3K/AKT signaling pathway.
Biochim Biophys Acta Mol Cell Res
January 2025
Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, China; Department of Thyroid and Breast Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, China. Electronic address:
SLC26A9 is a member of the Slc26a family of multifunctional anion transporters that function as Cl channels in the stomach. We reported for the first time that SLC26A9 is involved in gastric tumorigenesis. However, the role of SLC26A9 in breast cancer has not yet been investigated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!